Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Next Previous
Trial Profile

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use

Most Recent Events

  • 30 Jan 2025 Planned End Date changed from 13 Nov 2025 to 23 Jan 2026.
  • 15 Nov 2024 Planned End Date changed from 30 Sep 2027 to 13 Nov 2025.
  • 29 Nov 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top